The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer
Patients with localized prostate cancer (PCa) are often treated with radical prostatectomy (RP). However, more than 30% of such patients have high risk of recurrence. Salvage radiotherapy (SRT), androgen deprivation therapy (ADT) and combination of radiotherapy and ADT are the standard care for recu...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5b1ef9598f7c4d8e8d96ba5a87d1d3db |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5b1ef9598f7c4d8e8d96ba5a87d1d3db |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5b1ef9598f7c4d8e8d96ba5a87d1d3db2021-11-18T04:39:24ZThe Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer2234-943X10.3389/fonc.2021.705025https://doaj.org/article/5b1ef9598f7c4d8e8d96ba5a87d1d3db2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.705025/fullhttps://doaj.org/toc/2234-943XPatients with localized prostate cancer (PCa) are often treated with radical prostatectomy (RP). However, more than 30% of such patients have high risk of recurrence. Salvage radiotherapy (SRT), androgen deprivation therapy (ADT) and combination of radiotherapy and ADT are the standard care for recurrent PCa. Recently, high intensity focused ultrasound (HIFU) has gradually applied in the treatment of recurrent PCa. Here, we proposed a hypothesis that combined HIFU and bicalutamide 150mg as first line salvage therapy to treat patients with local recurrent PCa with visible lesions due to the following advantages: (1) HIFU is effective in reducing local tumor load, and bicalutamide 150mg is a feasible and safety option to combine with HIFU. (2) Compared with radiotherapy, HIFU plus 150mg bicalutamide is minimal invasiveness with fewer adverse effects and better quality of life(QOL); (3) Radiotherapy can be preserved as the second-line salvage method in the cases who are failure to HIFU and 150mg bicalutamide combination. More clinical trials are warranted to confirm this hypothesis in treatment with recurrent PCa.Jian-zhou CaoJian-zhou CaoRui SuRui SuRui SuJin-feng PanJin-feng PanZe-jun YanZe-jun YanQi MaQi MaQi MaQi MaFrontiers Media S.A.articlehigh intensity focused ultrasound (HIFU)anti-androgen therapybicalutamidehypothesislocal recurrent prostate cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
high intensity focused ultrasound (HIFU) anti-androgen therapy bicalutamide hypothesis local recurrent prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
high intensity focused ultrasound (HIFU) anti-androgen therapy bicalutamide hypothesis local recurrent prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jian-zhou Cao Jian-zhou Cao Rui Su Rui Su Rui Su Jin-feng Pan Jin-feng Pan Ze-jun Yan Ze-jun Yan Qi Ma Qi Ma Qi Ma Qi Ma The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| description |
Patients with localized prostate cancer (PCa) are often treated with radical prostatectomy (RP). However, more than 30% of such patients have high risk of recurrence. Salvage radiotherapy (SRT), androgen deprivation therapy (ADT) and combination of radiotherapy and ADT are the standard care for recurrent PCa. Recently, high intensity focused ultrasound (HIFU) has gradually applied in the treatment of recurrent PCa. Here, we proposed a hypothesis that combined HIFU and bicalutamide 150mg as first line salvage therapy to treat patients with local recurrent PCa with visible lesions due to the following advantages: (1) HIFU is effective in reducing local tumor load, and bicalutamide 150mg is a feasible and safety option to combine with HIFU. (2) Compared with radiotherapy, HIFU plus 150mg bicalutamide is minimal invasiveness with fewer adverse effects and better quality of life(QOL); (3) Radiotherapy can be preserved as the second-line salvage method in the cases who are failure to HIFU and 150mg bicalutamide combination. More clinical trials are warranted to confirm this hypothesis in treatment with recurrent PCa. |
| format |
article |
| author |
Jian-zhou Cao Jian-zhou Cao Rui Su Rui Su Rui Su Jin-feng Pan Jin-feng Pan Ze-jun Yan Ze-jun Yan Qi Ma Qi Ma Qi Ma Qi Ma |
| author_facet |
Jian-zhou Cao Jian-zhou Cao Rui Su Rui Su Rui Su Jin-feng Pan Jin-feng Pan Ze-jun Yan Ze-jun Yan Qi Ma Qi Ma Qi Ma Qi Ma |
| author_sort |
Jian-zhou Cao |
| title |
The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| title_short |
The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| title_full |
The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| title_fullStr |
The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| title_full_unstemmed |
The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer |
| title_sort |
use of high-intensity focused ultrasound (hifu) plus 150mg bicalutamide as first line salvage therapy for local recurrent prostate cancer |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/5b1ef9598f7c4d8e8d96ba5a87d1d3db |
| work_keys_str_mv |
AT jianzhoucao theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jianzhoucao theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jinfengpan theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jinfengpan theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT zejunyan theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT zejunyan theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima theuseofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jianzhoucao useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jianzhoucao useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT ruisu useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jinfengpan useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT jinfengpan useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT zejunyan useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT zejunyan useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer AT qima useofhighintensityfocusedultrasoundhifuplus150mgbicalutamideasfirstlinesalvagetherapyforlocalrecurrentprostatecancer |
| _version_ |
1718425102014480384 |